Let’s start with a quick review of place value, different bases, and our “Dots & Boxes” model for thinking about these ideas.

*The 1←2 Rule*

Whenever there are two dots in single box, they “explode,” disappear, and become one dot in the box to the left.

Example: Nine dots 1←2 in the system

We start by placing nine dots in the rightmost box.

Two dots in that box explode and become one dot in the box to the left.

Once again, two dots in that box explode and become one dot in the box to the left.

We do it again!

Hey, now we have more than two dots in the second box, so those can explode and move!

And the rightmost box still has more than two dots.

Keep going, until no box has two dots.

After all this, reading from left to right we are left with one dot, followed by zero dots, zero dots, and one final dot.

**Answer**The 2←1 code for nine dots is: 1001.

*The 1←3 Rule*

Whenever there are three dots in single box, they “explode,” disappear, and become one dot in the box to the left.

Example: Fifteen dots in the 1←3 system

Here’s what happens with fifteen dots:

**Answer**The 1←3 code for fifteen dots is: 120.

Definition

Recall that numbers written in the 1←2 system are called **binary** or **base two** numbers.

Numbers written in the 1←3 system are called **base three **numbers.

Numbers written in the 1←4 system are called **base four** numbers.

Numbers written in the 1←10 system are called **base ten** numbers.

In general, numbers written in the 1←*b* system are called **base b** numbers.

In a base *b* number system, each place represents a power of *b*, which means (b^{n}) for some whole number *n*. Remember this means *b* multiplied by itself *n* times:

- The right-most place is the units or ones place. (Why is this a power of
*b*?) - The second spot is the “
*b*” place. (In base ten, it’s the tens place.) - The third spot is the “(b^{2})” place. (In base ten, that’s the hundreds place. Note that (10^{2} = 100).)
- The fourth spot is the “(b^{3})” place. (In base ten, that’s the thousands place, since (10^{3} = 1000).)
- And so on.

notation

Whenever we’re dealing with numbers written in different bases, we use a subscript to indicate the base so that there can be no confusion. So:

- (102_{three}) is a base three number (read it as “one-zero-two base three”). This is the base three code for the number eleven.
- (222_{four}) is a base four number (read it as “two-two-two base four”). This is the base four code for the number forty-two.
- (54321_{ten}) is a base ten number. (It’s ok to say “fifty-four thousand three hundred and twenty-one.” Why?)

If the base is not written, we assume it’s base ten.

Remember: when you see the subscript, you are seeing the **code** for some number of dots.

Think / Pair / Share

Work through the two examples above carefully to be sure you remember and understand how the “Dots & Boxes” model works. Then answer these questions:

- When we write 9 in base 2, why do we write (1001_{two}) instead of just (11_{two})?

- When we write 15 in base 3, why do we write (120_{three}) instead of just (12_{three})?

- How many different digits do you need in a base 7 system? In a base 12 system? In a base
*b*system? How do you know?

## On Your Own

Work on the following exercises on your own or with a partner.

- In base 4, four dots in one box are worth one dot in the box one place to the left.
- What is the value of each box?
- How do you write (29_{ten}) in base 4?
- How do you write (132_{four}) in base 10?

- In our familiar base ten system, ten dots in one box are worth one dot in the box one place to the left.
- What is the value of each box?
- When we write the base ten number 7842:
- What quantity does the “7” represent?
- The “4” is four groups of what value?
- The “8” is eight groups of what value?
- The “2” is two groups of what value?

- Write the following numbers of dots in base two, base three, base five, and base eight. Draw the “Dots & Boxes” model if it helps you remember how to do this! (Note: these numbers are all written in base ten. When we don’t say otherwise, you should assume base ten.) $$(a); 2 qquad (b); 17 qquad (c); 27 qquad (d); 63 ldotp$$
- Convert these numbers to our more familiar base ten system. Draw out dots and boxes and “unexplode” the dots if it helps you remember. $$(a); 1101_{two} qquad (b); 102_{three} qquad (c); 24_{five} qquad (d); 24_{nine} ldotp$$

Think / Pair / Share

Quickly compute each of the following. Write your answer in the same base as the problem.

- (131_{ten}) times ten.

- (263207_{eight}) times eight.

- (563872_{nine}) times nine.

- Use the 1←10 system to explain why multiplying a whole number in base ten by ten results in simply appending a zero to the right end of the number.

- Suppose you have a whole number written in base
*b*. What is the effect of multiplying that number by*b*? Justify what you say.

## The importance of number sense to mathematics achievement in first and third grades ☆

Children's symbolic number sense was examined at the beginning of first grade with a short screen of competencies related to counting, number knowledge, and arithmetic operations. Conventional mathematics achievement was then assessed at the end of both first and third grades. Controlling for age and cognitive abilities (i.e., language, spatial, and memory), number sense made a unique and meaningful contribution to the variance in mathematics achievement at both first and third grades. Furthermore, the strength of the predictions did not weaken over time. Number sense was most strongly related to the ability to solve applied mathematics problems presented in various contexts. The number sense screen taps important intermediate skills that should be considered in the development of early mathematics assessments and interventions.

## Plain Language Summary

Dominant modes (i.e., coherent spatio-temporal patterns of variability) of the climate system, such as the Madden-Julian Oscillation (MJO), influence a wide range of weather and climate phenomena worldwide. The ability of state-of-the-art climate models to accurately simulate these modes is crucial for advancing our understanding of the climate system and reliably predicting its future trends. The Coupled Model Intercomparison Project Phase 6 (CMIP6) will be the foundation for the upcoming Intergovernmental Panel on Climate Change (IPCC) Sixth Assessment Report (AR6). Here, we use a wavelet-based spectral principal component analysis (wsPCA) to quantitatively assess how well historical simulations from 20 CMIP6 models capture MJO as compared to the observations. We first show that the MJO magnitude is not reproduced well in most of CMIP6 models. We then reveal that MJO-related precipitation variability in the Amazonia, Southwest Africa, and Maritime Continent is significantly underestimated in many CMIP6 models. Our results highlight the need to better simulate the coupled ocean-atmosphere dynamics in order to improve the representation of MJO in climate models and increase confidence in projected states of MJO for assessing future tropical and extratropical impacts.

## Quantum Wells, Wires and Dots: Theoretical and Computational Physics of Semiconductor Nanostructures, 4th Edition

*Quantum Wells, Wires and Dots* provides all the essential information, both theoretical and computational, to develop an understanding of the electronic, optical and transport properties of these semiconductor nanostructures. The book will lead the reader through comprehensive explanations and mathematical derivations to the point where they can design semiconductor nanostructures with the required electronic and optical properties for exploitation in these technologies.

This fully revised and updated 4th edition features new sections that incorporate modern techniques and extensive new material including:

- Properties of non-parabolic energy bands
- Matrix solutions of the Poisson and Schrödinger equations
- Critical thickness of strained materials
- Carrier scattering by interface roughness, alloy disorder and impurities
- Density matrix transport modelling
- Thermal modelling

Written by well-known authors in the field of semiconductor nanostructures and quantum optoelectronics, this user-friendly guide is presented in a lucid style with easy to follow steps, illustrative examples and questions and computational problems in each chapter to help the reader build solid foundations of understanding to a level where they can initiate their own theoretical investigations. Suitable for postgraduate students of semiconductor and condensed matter physics, the book is essential to all those researching in academic and industrial laboratories worldwide.

## 2 Answers 2

Let me fill in a few details of Noah's excellent answer. The empty theory $T$ in the language $mathcal*every* set. These are also called the tautologies of the predicate calculus. For instance, the following is a theorem of $T$ : $forall vforall w(v=wvee v
eq w),$ since it is true in every set (ie, true in every model of $T$ ). On the other hand, consider the $mathcal*not* a theorem of $T$ , since there are models of $T$ in which it does not hold. For example, consider a model $

Now, recall that $S_0(T)$ is the set of all complete (and consistent) $mathcal*every* $mathcal

For a less vacuous example, consider the sentence $phiequivexists vexists w(v
eq w)$ . Then both $[phi]$ and $[
egphi]$ are non-empty. Indeed, if $M$ is a model of $phi$ (say $M=

So, this is the topology we're working with. Recall that a point $x$ in an arbitrary topological space $X$ is "isolated" if $~~$ is open. As an exercise, show that this holds if and only if there exists an $mathcal~~~~$ . Furthermore, can you show that, for such $phi$ , we have $Tmodelsphi opsi$ for every $psiin S$ ? We then say that $S$ is ~~*isolated* by $phi$ . As a final hint, to complement Noah's answer, consider the sentence $phi_nequivexists v_1dotsexists v_nigwedge_*v_i
eq v_jwedgeforall wigvee_ ^n w=v_i.$ Up to isomorphism, what does a model of $phi_n$ look like? (Can there be two non-isomorphic models of $phi_n$ ?) In particular, what can you conclude about the open set $[phi_n]subseteq S_0(T)$ ? (Remember that two isomorphic $mathcal*

* *

**Edit:** Okay, here's a complete solution to the question. At each stage, try to read a small bit at a time and work out the rest for yourself! For each $ninmathbb*precisely* (and no more than) $n$ elements. Now, because $mathcal*any* function is an $mathcal

*
*

*
*

Now, there are $mathcal*any* $ninmathbb*infinite* models have the same complete $mathcal

Now, we first claim that $S_0(T)=

To see this, suppose $phi$ is an $mathcal*v_i
eq v_j$ appears in $Delta$ . We will then have $MmodelsDelta$ for any set $M$ such that $kleqslant|M|inmathbb $ and $T_<|M|>
otin[phi]$ , meaning that $Delta$ is consistent. So, by compactness, $Sigma$ is consistent, and hence we can find a model $MmodelsSigma$ . Then $M$ is infinite (why?), so $operatorname_mathcal*

* *

*Seeing quadratics in a new light: secondary mathematics pre-service teachers’ creation of figural growing patterns*

Teachers whose mathematical meanings support understanding across different contexts are likely to convey them in productive ways for coherent student learning. This exploratory study sought to elicit 67 secondary mathematics pre-service teachers’ (PSTs) meanings for quadratics with growing pattern creation and multiple translation tasks. A framework for categorizing their patterns, in terms of structural correspondence to quadratic equation forms, is shared. PSTs’ translations and explanations were analyzed using an existing framework for representational fluency. Evidence was found for some PSTs applying prior productive meanings to an unfamiliar context and others discovering new meanings. It was found that some PSTs were not able to draw on their prior knowledge of quadratic functions successfully, and possible reasons for this are explored. Successful figural pattern creation was found to be associated with higher representational fluency. Seven PSTs were also interviewed to probe their cognitive and affective experiences with a “new” type of quadratics task several described “aha” moments and used emotional languages like “horror” and “delight”. Implications for learning to teach quadratic functions, creative visualization tasks and future research are discussed.

This is a preview of subscription content, access via your institution.

## Upper and Lower Deviations of the Speed

This section is devoted to the proof of Lemma 3.2 and Corollary 3.3. We will prove Lemma 3.2 for (v_+) only but exactly the same proof, with symmetric arguments, holds for (v_-) .

### Proof of corollaries

We start by showing how Lemma 3.2 implies Corollary 3.3.

### Proof of Corollary 3.3

First note that, by the definition of (v_+( ho )) and (v_-( ho )) , we have that, for any (epsilon >0) ,

Note also that, for any (v_1,v_2in mathbb

We start by showing that either (v_+(
ho )ge 0) or (v_-(
ho ) le 0) . Indeed, assume that (v_+(
ho )<0) and (v_-(
ho )>0) and fix any (epsilon in (0,v_-(
ho )/4)) . Lemma 3.2 implies that, for (H in mathbb

Since (epsilon <v_-(
ho )-epsilon ) , we obtain from (5.1) and (5.3) that (p_

_*i* is large enough. This contradicts (5.2).

Now consider the case (v_+(
ho )ge 0) . Assume, by contradiction, (v_-(
ho )>v_+(
ho )) . Fix (epsilon in (0,(v_-(
ho )-v_+(
ho ))/4)) so that (v_+(
ho )+epsilon <v_-(
ho )-epsilon ) . By Lemma 3.2, for any (Hin mathbb *i* is large enough, we obtain from (5.2) that (p_

_

By a symmetric argument, (v_-( ho )le 0) implies (v_-( ho )le v_+( ho )) . This completes the proof that (v_-( ho )le v_+( ho )) . (square )

Now, we prove that Theorems 3.4 and 3.5 imply Theorem 2.2, stating that the random walk on the Exclusion process with density 1/2 has zero speed when (p_circ =1-p_ullet ) .

### Proof of Theorem 2.2

Note that the law of the exclusion process with ( ho =1/2) is invariant under flipping colors (ullet leftrightarrow circ ) . Thus, for any (p, q in [0,1]) we have (mathbb

^<1/2>_

= mathbb

^<1/2>_) which implies

Furthermore, in the particular case (q = 1-p) we have, for any (
ho ge 0) , any (yin mathbb

$egin

^< ho >_

ig [ X^y_H - pi _1(y) in Aig ] = mathbb

^<
ho >_ ig [- ig (X^y_H - pi _1(y)ig ) in A ig ]. end

## Volume 3

### 3.02.4.11 Ordinary Residuals versus Predicted Residuals

This scatterplot has the predicted residuals *e*_{i,−i} on the horizontal axis and the ordinary residuals *e*_{i} on the vertical axis 7 ( **Figure 23** ). It is expected that the residuals and the predicted residuals should be of about the same size. Hence, the values are expected to fall randomly at the center along the diagonal line of the plot. A *y*-outlier will be badly fitted. Hence, it will have both large *e*_{i} and large *e*_{i,−i} (point A). A bad leverage point will be fitted much better when it is included in the model than when it is excluded hence its *e*_{i,−i} will be much larger than its *e*_{i} (point B).

Figure 23 . Ordinary residuals *e*_{i} versus predicted residuals *e*_{i,−i}. Point A is a *y*-outlier. Point B is a bad leverage point.

## References

Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? *Nat. Rev. Drug Discov.* **3**, 711–716 (2004).

Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. *Nat. Rev. Drug Discov.* **4**, 145–160 (2005).

Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. *Cancer Res.* **46**, 6387–6392 (1986). **A seminal work on the EPR effect in cancer that essentially laid the foundation for the use of nanotherapeutics, including liposomes and polymer-drug conjugates, as treatment modalities.**

Maeda, H., Nakamura, H. & Fang, J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. *Adv. Drug Deliv. Rev.* **65**, 71–79 (2013).

Azzopardi, E.A., Ferguson, E.L. & Thomas, D.W. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. *J. Antimicrob. Chemother.* **68**, 257–274 (2013).

Marti, C.N. et al. Endothelial dysfunction, arterial stiffness, and heart failure. *J. Am. Coll. Cardiol.* **60**, 1455–1469 (2012).

Zhang, L. et al. Nanoparticles in medicine: therapeutic applications and developments. *Clin. Pharmacol. Ther.* **83**, 761–769 (2008).

Safra, T. et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. *Ann. Oncol.* **11**, 1029–1033 (2000).

Barenholz, Y. Doxil(R)–the first FDA-approved nano-drug: lessons learned. *J. Control. Release* **160**, 117–134 (2012).

Hawkins, M.J., Soon-Shiong, P. & Desai, N. Protein nanoparticles as drug carriers in clinical medicine. *Adv. Drug Deliv. Rev.* **60**, 876–885 (2008).

Gradishar, W.J. et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J. Clin. Oncol.* **23**, 7794–7803 (2005).

O'Brien, M.E. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann. Oncol.* **15**, 440–449 (2004).

Ferrari, M. Frontiers in cancer nanomedicine: directing mass transport through biological barriers. *Trends Biotechnol.* **28**, 181–188 (2010).

Bertrand, N., Wu, J., Xu, X., Kamaly, N. & Farokhzad, O.C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. *Adv. Drug Deliv. Rev.* **66**, 2–25 (2014).

Mura, S., Nicolas, J. & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. *Nat. Mater.* **12**, 991–1003 (2013).

Park, K. Facing the truth about nanotechnology in drug delivery. *ACS Nano* **7**, 7442–7447 (2013).

Venditto, V.J. & Szoka, F.C. Cancer nanomedicines: so many papers and so few drugs!. *Adv. Drug Deliv. Rev.* **65**, 80–88 (2013).

Patel, H.M. & Moghimi, S.M. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - The concept of tissue specificity. *Adv. Drug Deliv. Rev.* **32**, 45–60 (1998).

Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. *Nat. Nanotechnol.* **8**, 772–781 (2013).

Nel, A.E. et al. Understanding biophysicochemical interactions at the nano-bio interface. *Nat. Mater.* **8**, 543–557 (2009). **One of the most comprehensive reviews on the subject of nanoparticle protein coronas and implications on nanoparticle fate.**

Sahay, G., Alakhova, D.Y. & Kabanov, A.V. Endocytosis of nanomedicines. *J. Control. Release* **145**, 182–195 (2010).

Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. *Nat. Nanotechnol.* **8**, 137–143 (2013). **Excellent study highlighting the dynamic nature of nanoparticles following protein corona formation, and the detrimental effects this has on active targeting strategies.**

Docter, D. et al. Quantitative profiling of the protein coronas that form around nanoparticles. *Nat. Protoc.* **9**, 2030–2044 (2014).

Röcker, C., Potzl, M., Zhang, F., Parak, W.J. & Nienhaus, G.U. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. *Nat. Nanotechnol.* **4**, 577–580 (2009).

Harris, J.M. & Chess, R.B. Effect of pegylation on pharmaceuticals. *Nat. Rev. Drug Discov.* **2**, 214–221 (2003).

Hamilton, A. et al. EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer. *Ann. Oncol.* **13**, 910–918 (2002).

Guo, S.T. & Huang, L. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. *J. Nanomater.* **2011**, 742895 (2011).

Li, S.D. & Huang, L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. *Biochim. Biophys. Acta* **1788**, 2259–2266 (2009).

Rodriguez, P.L. et al. Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. *Science* **339**, 971–975 (2013). **An excellent study involving nanoparticle 'camouflaging' or 'biomimicry' for evasion of the MPS, highlighting consequent enhanced tumor accumulation and efficacy.**

Parodi, A. et al. Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. *Nat. Nanotechnol.* **8**, 61–68 (2013).

Hu, C.M. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. *Proc. Natl. Acad. Sci. USA* **108**, 10980–10985 (2011).

Kreuter, J. et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. *J. Drug Target.* **10**, 317–325 (2002).

Sica, A. & Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. *J. Clin. Invest.* **117**, 1155–1166 (2007).

Woollard, K.J. & Geissmann, F. Monocytes in atherosclerosis: subsets and functions. *Nat. Rev. Cardiol.* **7**, 77–86 (2010).

Prapainop, K., Witter, D.P. & Wentworth, P. Jr. A chemical approach for cell-specific targeting of nanomaterials: small-molecule-initiated misfolding of nanoparticle corona proteins. *J. Am. Chem. Soc.* **134**, 4100–4103 (2012).

Decuzzi, P., Pasqualini, R., Arap, W. & Ferrari, M. Intravascular delivery of particulate systems: does geometry really matter? *Pharm. Res.* **26**, 235–243 (2009).

Arvizo, R.R. et al. Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. *PLoS ONE* **6**, e24374 (2011).

Yao, C. et al. Highly biocompatible zwitterionic phospholipids coated upconversion nanoparticles for efficient bioimaging. *Anal. Chem.* **86**, 9749–9757 (2014).

Decuzzi, P., Lee, S., Bhushan, B. & Ferrari, M. A theoretical model for the margination of particles within blood vessels. *Ann. Biomed. Eng.* **33**, 179–190 (2005).

Tan, J., Shah, S., Thomas, A., Ou-Yang, H.D. & Liu, Y. The influence of size, shape and vessel geometry on nanoparticle distribution. *Microfluid. Nanofluidics* **14**, 77–87 (2013).

Shah, S., Liu, Y., Hu, W. & Gao, J. Modeling particle shape-dependent dynamics in nanomedicine. *J. Nanosci. Nanotechnol.* **11**, 919–928 (2011).

Alexiou, C. et al. Locoregional cancer treatment with magnetic drug targeting. *Cancer Res.* **60**, 6641–6648 (2000).

Gentile, F. et al. The effect of shape on the margination dynamics of non-neutrally buoyant particles in two-dimensional shear flows. *J. Biomech.* **41**, 2312–2318 (2008).

Tasciotti, E. et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. *Nat. Nanotechnol.* **3**, 151–157 (2008).

Chiappini, C. et al. Tailored porous silicon microparticles: fabrication and properties. *ChemPhysChem* **11**, 1029–1035 (2010).

van de Ven, A.L. et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. *J. Control. Release* **158**, 148–155 (2012).

Tanaka, T. et al. Sustained small interfering RNA delivery by mesoporous silicon particles. *Cancer Res.* **70**, 3687–3696 (2010).

Chen, X. et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. *Nature* **508**, 103–107 (2014).

Dave, B. et al. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. *Proc. Natl. Acad. Sci. USA* **111**, 8838–8843 (2014).

von Maltzahn, G. et al. Nanoparticles that communicate *in vivo* to amplify tumour targeting. *Nat. Mater.* **10**, 545–552 (2011). **An inventive approach for targeting of nanoparticles involving 'biological communication' between different injectable constructs for enhanced uptake into tumors.**

Murphy, E.A. et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. *Proc. Natl. Acad. Sci. USA* **105**, 9343–9348 (2008).

Thurston, G. et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. *J. Clin. Invest.* **101**, 1401–1413 (1998). **An interesting study demonstrating the potential of using surface charge of nanoparticles, in this case cationic liposomes, as a means to target therapeutics to angiogenic tumor vasculature by means of enhanced endothelial cell uptake.**

Yokoi, K. et al. Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. *Cancer Lett.* **345**, 48–55 (2014).

Yokoi, K. et al. Capillary-wall collagen as a biophysical marker of nanotherapeutic permeability into the tumor microenvironment. *Cancer Res.* **74**, 4239–4246 (2014).

Heldin, C.H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure - an obstacle in cancer therapy. *Nat. Rev. Cancer* **4**, 806–813 (2004).

Chauhan, V.P. et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. *Nat. Nanotechnol.* **7**, 383–388 (2012).

Jain, R.K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. *J. Clin. Oncol.* **31**, 2205–2218 (2013).

Jain, R.K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. *Nat. Rev. Clin. Oncol.* **7**, 653–664 (2010).

Monsky, W.L. et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. *Cancer Res.* **59**, 4129–4135 (1999).

Diop-Frimpong, B., Chauhan, V.P., Krane, S., Boucher, Y. & Jain, R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. *Proc. Natl. Acad. Sci. USA* **108**, 2909–2914 (2011).

Miller, C.R., Bondurant, B., McLean, S.D., McGovern, K.A. & O'Brien, D.F. Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. *Biochemistry* **37**, 12875–12883 (1998).

Gratton, S.E. et al. The effect of particle design on cellular internalization pathways. *Proc. Natl. Acad. Sci. USA* **105**, 11613–11618 (2008).

Osaka, T., Nakanishi, T., Shanmugam, S., Takahama, S. & Zhang, H. Effect of surface charge of magnetite nanoparticles on their internalization into breast cancer and umbilical vein endothelial cells. *Colloids Surf. B Biointerfaces* **71**, 325–330 (2009).

Serda, R.E. et al. The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. *Biomaterials* **30**, 2440–2448 (2009).

Lee, Y. et al. A protein nanocarrier from charge-conversion polymer in response to endosomal pH. *J. Am. Chem. Soc.* **129**, 5362–5363 (2007).

Yuan, Y.Y. et al. Surface charge switchable nanoparticles based on zwitterionic polymer for enhanced drug delivery to tumor. *Adv. Mater.* **24**, 5476–5480 (2012). **A highly innovative approach towards site-specific, externally stimulated nanoparticle surface charge conversion that permits for prolonged circulation and heightened tumor cell internalization: a perfect example of design considerations that take into account different barriers to nanoparticle drug delivery.**

Le Roy, C. & Wrana, J.L. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. *Nat. Rev. Mol. Cell Biol.* **6**, 112–126 (2005).

Gould, G.W. & Lippincott-Schwartz, J. New roles for endosomes: from vesicular carriers to multi-purpose platforms. *Nat. Rev. Mol. Cell Biol.* **10**, 287–292 (2009).

Luo, D. & Saltzman, W.M. Synthetic DNA delivery systems. *Nat. Biotechnol.* **18**, 33–37 (2000).

Bareford, L.M. & Swaan, P.W. Endocytic mechanisms for targeted drug delivery. *Adv. Drug Deliv. Rev.* **59**, 748–758 (2007).

Martens, T.F., Remaut, K., Demeester, J., De Smedt, S.C. & Braeckmans, K. Intracellular delivery of nanomaterials: how to catch endosomal escape in the act. *Nano Today* **9**, 344–364 (2014).

Wasungu, L. & Hoekstra, D. Cationic lipids, lipoplexes and intracellular delivery of genes. *J. Control. Release* **116**, 255–264 (2006).

Chou, L.Y., Ming, K. & Chan, W.C. Strategies for the intracellular delivery of nanoparticles. *Chem. Soc. Rev.* **40**, 233–245 (2011).

Dauty, E., Remy, J.S., Zuber, G. & Behr, J.P. Intracellular delivery of nanometric DNA particles via the folate receptor. *Bioconjug. Chem.* **13**, 831–839 (2002).

Gradishar, W.J. Albumin-bound paclitaxel: a next-generation taxane. *Expert Opin. Pharmacother.* **7**, 1041–1053 (2006).

Ibrahim, N.K. et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. *J. Clin. Oncol.* **23**, 6019–6026 (2005). **Clinical trial of nanoparticle albumin-bound paclitaxel in metastatic breast cancer patients, highlighting not only the therapeutic potential of paclitaxel, but its benefits with regards to reduced side effects compared to the conventional formulation containing Cremophor EL.**

Szakács, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C. & Gottesman, M.M. Targeting multidrug resistance in cancer. *Nat. Rev. Drug Discov.* **5**, 219–234 (2006).

Rees, D.C., Johnson, E. & Lewinson, O. ABC transporters: the power to change. *Nat. Rev. Mol. Cell Biol.* **10**, 218–227 (2009).

Aller, S.G. et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. *Science* **323**, 1718–1722 (2009).

Gottesman, M.M., Fojo, T. & Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat. Rev. Cancer* **2**, 48–58 (2002).

Fletcher, J.I., Haber, M., Henderson, M.J. & Norris, M.D. ABC transporters in cancer: more than just drug efflux pumps. *Nat. Rev. Cancer* **10**, 147–156 (2010).

Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. *Nat. Rev. Cancer* **5**, 275–284 (2005).

Wu, J. et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. *J. Pharm. Pharm. Sci.* **10**, 350–357 (2007).

Wong, H.L., Bendayan, R., Rauth, A.M. & Wu, X.Y. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. *J. Control. Release* **116**, 275–284 (2006).

Patel, N.R., Rathi, A., Mongayt, D. & Torchilin, V.P. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. *Int. J. Pharm.* **416**, 296–299 (2011).

Xiong, X.B. & Lavasanifar, A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. *ACS Nano* **5**, 5202–5213 (2011).

Batrakova, E.V. & Kabanov, A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. *J. Control. Release* **130**, 98–106 (2008).

Sosnik, A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review. *Adv. Drug Deliv. Rev.* **65**, 1828–1851 (2013).

Lee, Y., Park, S.Y., Mok, H. & Park, T.G. Synthesis, characterization, antitumor activity of pluronic mimicking copolymer micelles conjugated with doxorubicin via acid-cleavable linkage. *Bioconjug. Chem.* **19**, 525–531 (2008).

Tian, Y., Bromberg, L., Lin, S.N., Hatton, T.A. & Tam, K.C. Complexation and release of doxorubicin from its complexes with pluronic P85-b-poly(acrylic acid) block copolymers. *J. Control. Release* **121**, 137–145 (2007).

Longmire, M., Choyke, P.L. & Kobayashi, H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. *Nanomedicine (Lond.)* **3**, 703–717 (2008).

Black, K.C. et al. Radioactive 198Au-doped nanostructures with different shapes for in vivo analyses of their biodistribution, tumor uptake, and intratumoral distribution. *ACS Nano* **8**, 4385–4394 (2014).

Xiao, K. et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. *Biomaterials* **32**, 3435–3446 (2011).

Sheridan, C. Gene therapy finds its niche. *Nat. Biotechnol.* **29**, 121–128 (2011).

Kay, M.A., Glorioso, J.C. & Naldini, L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. *Nat. Med.* **7**, 33–40 (2001).

Levine, R.M., Pearce, T.R., Adil, M. & Kokkoli, E. Preparation and characterization of liposome-encapsulated plasmid DNA for gene delivery. *Langmuir* **29**, 9208–9215 (2013).

Dobson, J. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. *Gene Ther.* **13**, 283–287 (2006).

Pissuwan, D., Niidome, T. & Cortie, M.B. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. *J. Control. Release* **149**, 65–71 (2011).

Lechardeur, D. et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. *Gene Ther.* **6**, 482–497 (1999).

Anderson, D.J. & Hetzer, M.W. Nuclear envelope formation by chromatin-mediated reorganization of the endoplasmic reticulum. *Nat. Cell Biol.* **9**, 1160–1166 (2007).

Raices, M. & D'Angelo, M.A. Nuclear pore complex composition: a new regulator of tissue-specific and developmental functions. *Nat. Rev. Mol. Cell Biol.* **13**, 687–699 (2012).

Hu, Y., Haynes, M.T., Wang, Y., Liu, F. & Huang, L. A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. *ACS Nano* **7**, 5376–5384 (2013).

Choi, H.S. et al. Renal clearance of quantum dots. *Nat. Biotechnol.* **25**, 1165–1170 (2007).

Braet, F. et al. Contribution of high-resolution correlative imaging techniques in the study of the liver sieve in three-dimensions. *Microsc. Res. Tech.* **70**, 230–242 (2007).

Chen, L.T. & Weiss, L. The role of the sinus wall in the passage of erythrocytes through the spleen. *Blood* **41**, 529–537 (1973).

Hobbs, S.K. et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc. Natl. Acad. Sci. USA* **95**, 4607–4612 (1998).

Cabral, H. et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. *Nat. Nanotechnol.* **6**, 815–823 (2011). **Excellent study that highlights the effect of nanoparticle size on accumulation and penetration of nanoparticles in hypovascular tumors.**

Maeda, H., Wu, J., Sawa, T., Matsumura, Y. & Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. *J. Control. Release* **65**, 271–284 (2000).

Geng, Y. et al. Shape effects of filaments versus spherical particles in flow and drug delivery. *Nat. Nanotechnol.* **2**, 249–255 (2007).

Champion, J.A. & Mitragotri, S. Role of target geometry in phagocytosis. *Proc. Natl. Acad. Sci. USA* **103**, 4930–4934 (2006). **Seminal work on the effect of particle geometry on macrophage uptake, demonstrating that the architectural design parameter of curvature drives phagocytosis.**

Champion, J.A. & Mitragotri, S. Shape induced inhibition of phagocytosis of polymer particles. *Pharm. Res.* **26**, 244–249 (2009).

Christian, D.A. et al. Flexible filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. *Mol. Pharm.* **6**, 1343–1352 (2009).

Park, J.H. et al. Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting. *Small* **5**, 694–700 (2009).

Alexis, F., Pridgen, E., Molnar, L.K. & Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Mol. Pharm.* **5**, 505–515 (2008).

Yamamoto, Y., Nagasaki, Y., Kato, Y., Sugiyama, Y. & Kataoka, K. Long-circulating poly(ethylene glycol)-poly(d,l-lactide) block copolymer micelles with modulated surface charge. *J. Control. Release* **77**, 27–38 (2001).

Moghimi, S.M., Hunter, A.C. & Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. *Pharmacol. Rev.* **53**, 283–318 (2001).

Zhang, L. et al. Softer zwitterionic nanogels for longer circulation and lower splenic accumulation. *ACS Nano* **6**, 6681–6686 (2012).

Merkel, T.J. et al. The effect of particle size on the biodistribution of low-modulus hydrogel PRINT particles. *J. Control. Release* **162**, 37–44 (2012).

Cui, J. et al. Super-soft hydrogel particles with tunable elasticity in a microfluidic blood capillary model. *Adv. Mater.* **26**, 7295–7299 (2014).

Attia, A.B.E. et al. The effect of kinetic stability on biodistribution and anti-tumor efficacy of drug-loaded biodegradable polymeric micelles. *Biomaterials* **34**, 3132–3140 (2013).

van Nostrum, C.F. Covalently cross-linked amphiphilic block copolymer micelles. *Soft Matter* **7**, 3246–3259 (2011).

## Efficient high-dimensional metamodeling strategy using recursive decomposition coupled with sequential sampling method

Metamodel has been widely used to solve computationally expensive engineering problems, and there have been many studies on how to efficiently and accurately generate metamodels with limited number of samples. However, applications of these methods could be limited in high-dimensional problems since it is still challenging due to curse of dimensionality to generate accurate metamodels in high-dimensional design space. In this paper, recursive decomposition coupled with a sequential sampling method is proposed to identify latent decomposability and efficiently generate high-dimensional metamodels. Whenever a new sample is inserted, variable decomposition is repeatedly performed using interaction estimation from a full-dimension Kriging metamodel. The sampling strategy of the proposed method consists of two units: decomposition unit and accuracy improvement unit. Using the proposed method, latent decomposability of a function can be identified using reasonable number of samples, and a high-dimensional metamodel can be generated very efficiently and accurately using the identified decomposability. Numerical examples using both decomposable and indecomposable problems show that the proposed method shows reasonable decomposition results, and thus improves metamodel accuracy using similar number of samples compared with conventional methods.

This is a preview of subscription content, access via your institution.

## Forecasting: Principles and Practice (2nd ed)

Holt (1957) and Winters (1960) extended Holt’s method to capture seasonality. The Holt-Winters seasonal method comprises the forecast equation and three smoothing equations — one for the level (ell_t) , one for the trend (b_t) , and one for the seasonal component (s_t) , with corresponding smoothing parameters (alpha) , (eta^*) and (gamma) . We use (m) to denote the frequency of the seasonality, i.e., the number of seasons in a year. For example, for quarterly data (m=4) , and for monthly data (m=12) .

There are two variations to this method that differ in the nature of the seasonal component. The additive method is preferred when the seasonal variations are roughly constant through the series, while the multiplicative method is preferred when the seasonal variations are changing proportional to the level of the series. With the additive method, the seasonal component is expressed in absolute terms in the scale of the observed series, and in the level equation the series is seasonally adjusted by subtracting the seasonal component. Within each year, the seasonal component will add up to approximately zero. With the multiplicative method, the seasonal component is expressed in relative terms (percentages), and the series is seasonally adjusted by dividing through by the seasonal component. Within each year, the seasonal component will sum up to approximately (m) .

### Holt-Winters’ additive method

The component form for the additive method is: [egin

The equation for the seasonal component is often expressed as [ s_

### Holt-Winters’ multiplicative method

The component form for the multiplicative method is: [egin

### Example: International tourist visitor nights in Australia

We apply Holt-Winters’ method with both additive and multiplicative seasonality to forecast quarterly visitor nights in Australia spent by international tourists. Figure 7.6 shows the data from 2005, and the forecasts for 2016–2017. The data show an obvious seasonal pattern, with peaks observed in the March quarter of each year, corresponding to the Australian summer.

Figure 7.6: Forecasting international visitor nights in Australia using the Holt-Winters method with both additive and multiplicative seasonality.

Table 7.3: Applying Holt-Winters’ method with additive seasonality for forecasting international visitor nights in Australia. Notice that the additive seasonal component sums to approximately zero. The smoothing parameters and initial estimates for the components have been estimated by minimising RMSE ( (alpha=0.306) , (eta^*=0.0003) , (gamma=0.426) and RMSE (=1.763) ).(t) | (y_t) | (ell_t) | (b_t) | (s_t) | (hat |
---|

(t) | (y_t) | (ell_t) | (b_t) | (s_t) | (hat |
---|

The applications of both methods (with additive and multiplicative seasonality) are presented in Tables 7.3 and 7.4 respectively. Because both methods have exactly the same number of parameters to estimate, we can compare the training RMSE from both models. In this case, the method with multiplicative seasonality fits the data best. This was to be expected, as the time plot shows that the seasonal variation in the data increases as the level of the series increases. This is also reflected in the two sets of forecasts the forecasts generated by the method with the multiplicative seasonality display larger and increasing seasonal variation as the level of the forecasts increases compared to the forecasts generated by the method with additive seasonality.

The estimated states for both models are plotted in Figure 7.7. The small value of (gamma) for the multiplicative model means that the seasonal component hardly changes over time. The small value of (eta^<*>) for the additive model means the slope component hardly changes over time (check the vertical scale). The increasing size of the seasonal component for the additive model suggests that the model is less appropriate than the multiplicative model.

Figure 7.7: Estimated components for the Holt-Winters method with additive and multiplicative seasonal components.

### Holt-Winters’ damped method

Damping is possible with both additive and multiplicative Holt-Winters’ methods. A method that often provides accurate and robust forecasts for seasonal data is the Holt-Winters method with a damped trend and multiplicative seasonality: [egin

### Example: Holt-Winters method with daily data

The Holt-Winters method can also be used for daily type of data, where the seasonal period is (m=7) , and the appropriate unit of time for (h) is in days. Here, we generate daily forecasts for the last five weeks for the hyndsight data, which contains the daily pageviews on the Hyndsight blog for one year starting April 30, 2014.

Figure 7.8: Forecasts of daily pageviews on the Hyndsight blog.

Clearly the model has identified the weekly seasonal pattern and the increasing trend at the end of the data, and the forecasts are a close match to the test data.